	ON DISCLOSUF	RE CITATION	Attorney Docket 44921-5038-U			Application No. 09/917,800	
(Use several sheets if necessary) PTO Form 1449			Applicants: Donna Mendrick et al.		PAGE 1 of 1		
			Filing Date: July 3	1, 2001	Group Art Unit: Unassigned		
<del></del>					<del></del>	<del></del>	
	<del> </del>	U.S. PA	TENT DOCUMENTS	<u>L</u>			
Examiner	Document	Date	Name	Class	Sub	Filing Date	
Pitit	Number				Class		
cor con s	6,160,105	2000-12-12	Cunningham et al.			1998-10-13	
COC 2001 2	5,811,231	1998-09-22	Farr et al.			1995-07-21	
1 4							
ARIT					L.		
3 TRADEMARKS							
			PATENT DOCUMENTS				
[	Document	Date	Country	Class	Sub	Translation	
	Number WO 04/17209	1004 00 04	D.C.		Class	YES NO	
_	WO 94/17208	1994-08-04	PCT				
	WO 97/13877	1997-04-17	PCT		<u> </u>		
	WO 97/16732 WO 99/12118	1997-05-09	PCT			<del> </del>	
	WO 00/12760	1999-03-11 2000-03-09	PCT				
	WO 00/12/80 WO 00/28092	2000-03-09	PCT		<b>⊢</b> ⊢ ⊢ ⊢ ⊢	ECHIVE	
	WO 00/28092 WO 00/39336	2000-03-18	PCT				
	WO 00/39330 WO 00/47761	2000-07-00	PCP	<del></del>	-	MAR 0 7 200	
	WO 00/47/01 WO 00/63435		PCT		ļ	+	
	WO 00/03433	2000-10-26	PCT		+ TECH	CEEK 1600/	
	WO 01/14425	2001-03-01	PCT			1 0 2 2 . 1 . 1 0 0 0 /	
	WO 01/36684 /	2001-05-25	PCT				
•	WO 01/2004%	2001-03-22	PCT		<del> </del>		
	WO 01/23886	2001-04-05	PCT			<del>  </del>	
	WO 01/25473	2001-04-12	PCT				
	WO 01/32928	2001-05-10	PCT			<del> </del>	
	WO 01/38579	2001-05-31	PCT		<del> </del>	1	
	WO 01/44512	2001-06-21	PCT		<del> </del>	<del>                                     </del>	
	WO 01/63279	2001-08-30	PCT		<del> </del>		
					<del>                                     </del>		
			· · · · · · · · · · · · · · · · · · ·				
	OTHER DO	CUMENTS (Includ	ling Author, Title, Date, Per	rtinent Pages, Et	c.)	<del></del>	
xaminer (	land	<b>'</b> ~	Date Considered	4/29/	B		
Examiner: Ini		<i></i>	ot citation is in conformance				

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Attorney Docket 44921-5038 Application No. 09/917,800 Applicant: Donna MENDRICK et al.				
		PTO Form 1449		Filing Date: July 31, 2	001	Group Art U	nit: <b>1645</b>	1631
			U.S. PATE	NT DOCUMENTS				
Initial		Patent No.	Issue Date	Name	Class	Sub- class		g Date
OBE	1.	6,403,778	6/11/2002	Cunningham et al.	536	22.1	8/28	3/1998
16 2 1 2002								
ADEMARK OF	<b>7</b>			THE SAME TO A CHILD AND SAME				
		ID ( BY		TENT DOCUMENT		CL	m	atio-
		Document No.	Publication Date	Country	Class	Sub- class	Transl Yes	<u>ation</u> No
en	2.	WO 02/31704	4/18/2002	U.S.A.	G06F	17/30		No
cM	3.	WO 99/27090	6/03/1999	Great Britain	C12N	12/12		No
				DOCHEMENTED				
			OTHER	DOCUMENTS				
cor	4.	Adamson & Harr	nan et al., Biochem.	Pharmacol., 45: 2289-2	2294 (1993)	(AB572)	act only	4)
	5.	Afshari et al., Ca	ncer Res., <b>59</b> : 4759	-4760 (1999)				
	6.	Ahotupa et al., C	arcinogenesis., 15:	863-868 (1994)				
	7.	Al-Bayati & Stol	s, Arch. Environ. C	ontam. Toxicol., <b>20</b> : 361	-365 (1991	)		
	8.		ol. Chem, <b>276</b> : 272					
	9.		Ameisen, Nature, 395: 117-119 (1998)					
	10.	Andersen & Barton, Environ. Health Perspect., 106: 349-355 (1998)						
	12.		Anderson et al., Mol. Carcinog., 26: 226-238 (1999)  Anderson et al., Toxicol. Appl. Pharmacol., 137: 75-89 (1996)					
	13.	Arano et al., Arzi	neimittelforschung,	<b>46</b> : 398-400 (1996)				
	14.	Atchison et al., L	Digestive Dis. Sci., 4	5: 614-620 (2000)	· -			-

RECEIVED AUG 2 2 2002

A CORN	ר אינוי אינו		Attornou Dockst	TECH CENTER 1600/2000
INFORMATION DISCLOSURE CITATION			Attorney Docket 44921-5038	09/917,800
	•	veral sheets if necessary)	Applicant: Donna MENDR	
<del> </del>		PTO Form 1449	Filing Date: July 31, 2001	Group Art Unit: 4645 16
col	15.	Bagetta et al., Biochem. Biophys. Re	es. Commun., 197: 1132-1139	(1993) (ABSTRACT ON I
	16.	Bajgar et al., Neurochem. Int., 24: 5	555-558 (1994)	
	17.	Baker et al., Chem. Res. Toxicol., 1	4: 1218-1231 (2001)	
	18.	Barner & Gray, Ann. Pharmacother		
	19.	Bartosiewicz et al., J. Pharmacol. E	Exp. Ther., <b>297</b> : 895-905 (2001	1)
	20.	Beck et al, Arch. Toxicol., 64: 210-2		
	21.	Becker et al., Alzheimer Dis. Assoc.		
	22.	Bedard et al., Antimicrob. Agents C		))
	23.	Bedossa et al., Hepatology, 19: 126	<del></del>	
	25.	Beierschmitt et al., Toxicol. Sci., 63		
	26.	Belury et al., Toxicol. Appl. Pharma		0067
_	27.	Berndt et al., Proc. Natl. Acad. Sci. Birge et al., Toxicol. Appl. Pharmac		
$\overline{}$	28.	Boelsterli et al., Cell Biol. Toxicol.,		
_	29.	Bort et al., J. Pharmacol. Exp. Ther		
<u> </u>	30.	Bosio and Borlak, Innovations in P.	·	5-75
A.A	31.	Bouchard et al., Liver, 13: 193-202		
en	32.	Bruck et al., Dig. Dis. Sci., 44: 1228		
-	33.	Burchiel et al., Toxicol. Sci., 59: 19		
	34.	Burczynski et al., Toxicol. Sci., 58:	399-415 (2000)	
	35.	Bursch et al., Arch. Toxicol., 69: 25	3-258 (1995)	
-	36.	Buttar et al., Toxicology., 6: 9-20 (1	976)	
	37.	Butterworth et al., Cancer Res., 49:	1075-1084 (1989)	

BY MR 5 / MR 3

RECEIVED

AUG 2 2 7002 Page 3 of 13

TRUBORM	ATIO	N DISCLOSURE CITATION	Attorney Docket	Application No. 1000	
			44921-5038	1.09/917,800	
	•	veral sheets if necessary)	Applicant: Donna MENDRICK	T	
		PTO Form 1449	Filing Date: July 31, 2001	Group Art Unit: 1645 1631	
COX	38.	Cai et al., J. Med. Chem., 41: 1970-	1979 (1998)	(ABSTRACT ONLY)	
	39.	Calabrese et al., J. Amer. College To	oxicol., 15: 62-69 (1996)		
	40.	Castell et al., Cell Biol. Toxicol., 13	3: 331-338 (1997)		
	41.	Chan et al., Proc. Natl. Acad. Sci. U	J.S.A, <b>98</b> : 4611-4616 (2001)		
	42.	Chanda et al., Hepatology, 21: 477-	486 (1995)		
	43.	Chen et al., J. Biol. Chem, 275: 22	619-22622 (2000)		
	44.	Chisholm et al., Am. J. Physiol., 270	<b>6</b> : G1165-G1173 (1999)		
	45.	Chou et al., Proc. Natl. Acad. Sci. U	J.S.A, <b>98</b> : 8113-8118 (2001)		
	46.	Christian et al., Toxicol. Appl. Phar	rmacol., <b>82</b> : 239-255 (1986)		
	47.	Clive et al., Fundam. Appl. Toxicol., 3: 587-602 (1983)			
	48.	Coles et al., Arch. Biochem. Biophy	rs., <b>264</b> : 253-260 (1988)		
	49.	Conforti et al., Agents Actions, 40:	176-180 (1993)		
	50.	Coni et al., Hepatology, 17: 1109-1	116 (1993)		
	51.	Corell et al., Acta Pharmacol. Toxio	col. (Copenh), 45: 232-239 (1979)		
	52.	Corton & Stauber, Toxicol. Sci., 58:	217-219 (2000)		
	53.	Corton et al., Cancer Lett., 134: 61-	-71 (1998)		
	54.	Corton et al., Cancer Lett., 137: 9-1	5 (1999)		
	55.	Corton et al., Mol. Pharmacol., 54:	463-473 (1998)		
	56.	Crosby et al., Toxicol. Appl. Pharm	acol., 169: 205-221 (2000)		
	57.	Cunningham et al., Ann. N.Y. Acad.	Sci., 919: 52-67 (2000)		
	58.	D'Mello et al., Exp. Toxicol. Pathol	l., <b>51</b> : 549-553 (1999)		
	59.	Davis et al., Cancer Res., 60: 2887-	2891 (2000)		
	60.	De Fabiani et al., J. Biol. Chem., 27	<b>76</b> : 30708-30716 (2001)		

NFORM	ATTO	N DISCLOSURE CITATION	Attorney Docket 44921-5038	Application No. 09/917,800
	•	everal sheets if necessary)	Applicant: Donna MENDRI	
		PTO Form 1449	Filing Date: July 31, 2001	Group Art Unit: 1645   637
wor	61.	Del Giudice et al., IL Farmaco., 51	: 693-698 (1996)	(ABSTRACT ONLY)
1	62.	Delaney & Timbrell, Xenobiotica.,	<b>25</b> : 1399-1410 (1995)	1
	63.	Diel et al., J. Steroid Biochem. Mol	l. Biol., 73: 1-10 (2000)	
	64.	Dodds & Rivory, Mol. Pharmacol.,	, <b>56</b> : 1346-1353 (1999)	
	65.	Dos Santos et al., J. Am. Soc. Neph.	rol., <b>8</b> : 361-367 (1997)	
	66.	Duivenvoorden et al., Biochem. Bio	ophys. Res. Commun., 215: 598-	605 (1995)
	67.	Dutar et al., Brain Res., 527: 32-40	(1990)	
	68.	Eadie et al., Med. Toxicol. Adverse	Drug Exp., 3: 85-106 (1988)	
	69.	Eldridge et al., Carcinogenesis, 11:	: 2245-2251 (1990)	
	70.	Ellis & Isaacs, Cancer Res., 45: 604	41-6050 (1985)	
	71.	Emmison et al., Biochim. Biophys.	Acta, 1083: 147-152 (1991)	
	72.	Enomoto et al., Toxicol. Sci., 59: 16	69-177 (2001)	
	73.	Falzon et al., Br. J. Exp. Pathol., 66	6: 527-534 (1985)	
	74.	Fan & Rozman, Toxicol. Lett., 75: 2	209-216 (1995)	
	75.	Fan et al., J. Biol. Chem, 271: 246	698-24710 (1996)	
	76.	Farag & Hassib, Clin. Sci. (Lond), 8	<b>84</b> : 387-390 (1993)	
	77.	Farr & Dunn, Toxicol. Sci., 50: 1-9	(1999)	
	78.	Fernandez-Tome & Sterin-Speziale	e, Pharmacology, <b>48</b> : 341-348 (1	994)
	79.	Ficazzola et al., Carcinogenesis, 22	2: 1271-1279 (2001)	
	80.	Fielden & Zacharewski, Toxicol. So	ci., <b>60</b> : 6-10 (2001)	
	81.	Fitten et al., J. Gerontol., 42: 681-6	685 (1987)	
	82.	Fracasso et al., Agents Actions, 22:	3-4 (1987)	
	83.	Fracasso et al., Agents Actions, 31:	313-316 (1990)	

## Me 5 / 2000

## RECEIVED

AUG 2 2 2002

INECEMATION DISCLOSURE CITATION Page 5 of 13 <u> AGGH GEN RER 1000/2</u> Attorney Docket 44921-5038 09/917,800 (Use several sheets if necessary) Applicant: Donna MENDRICK et al. Group Art Unit: 1645- 1631 PTO Form 1449 Filing Date: July 31, 2001 col 84. Froesch et al., J. Biol. Chem., 274: 6469-6475 (1999) ABSTRAOT ONLY 85. Frueh et al., Mol. Pharmacol., 51: 363-399 (1997) 86. Fulgencio et al., Biochem. Pharmacol., 62: 439-446 (2001) 87. Furr, Ann. N.Y. Acad. Sci., 761: 79-96 (1995) 88. Furr, Eur. Urol., 29: 83-95 (1996) 89. Ganem & Jefcoate, Toxicol. Appl. Pharmacol., 150: 68-75 (1998) 90. Garcia-Allan et al., J. Biochem. Mol. Toxicol.., 14: 65-72 (2000) 91. Gerhold et al., Physiol. Genomics, 5: 161-170 (2001) 92. Ghatineh et al., Arch. Toxicol., 66: 660-668 (1992) 93. Goll et al., Toxicol. Appl. Pharmacol., 160: 21-32 (1999) 94. Gram & Bentsen, Acta Neurol. Scand. Suppl., 97: 81-90 (1983) 95. Greaves et al., Cancer Res., 53: 3919-3924 (1993) 96. Green et al., Toxicol. Appl. Pharmacol., 76: 139-149 (1984) 97. Guardavaccaro et al., Mol. Cell. Biol., 20: 1797-17815 (2000) 98. Hamada et al., Hepatology, 21: 1455-1464 (1995) 99. Hamada et al., J. Hepatol., 30: 807-818 (1999) 100 Hargus et al., Chem. Res. Toxicol., 7: 575-582 (1994) 101 Hargus et al., Chem. Res. Toxicol., 8: 993-996 (1995) 102 Harries et al., Toxicol. In Vitro, 15: 399-405 (2001) 103 Hartung & Wendel, Biochem. Pharmacol., 42: 1129-1135 (1991) 104 He et al., J. Biol. Chem., 276: 20858-20865 (2001) 105 Hellriegel et al., Biochem. Pharmacol., 52: 1561-1568 (1996) 106 Hessel et al., Braz. J. Med. Biol. Res., 29: 793-796 (1996)

INFORM	IATIO	N DISCLOSURE CITATION	Attorney Docket 44921-5038	Application No. 09/917,800	
	(Use se	veral sheets if necessary)	Applicant: Donna MEND		
PTO Form 1449		Filing Date: July 31, 2001		1645- KG3 1	
cor	107	Hillstrom et al., Proc. Soc. Exp. Bio			
1	108	Hissink et al., Chem. Res. Toxicol.,	9: 1249-1256 (1996)	1	<b></b>
	109	Hogue, Chemical and Engineering	News, <b>79</b> : 33-34 (2001)		
	110	Hunter et al., Br. J. Pharmacol., 98	: 79-86 (1989)		
	111	Inohara et al., EMBO J., 17: 2526-2	2533 (1998)		
	112	Iredale et al., J. Clin. Invest., 102: 5	538-549 (1998)		
	113	Iswaran et al., J. Toxicol. Sci., 22: 7	75-88 (1997)		
	114	Itoh et al., Behav. Brain Res., 83: 1	65-167 (1997)		
	115	Itoh et al., Eur. J. Pharmacol., 322:	: 11-19 (1997)		
	116	Izumi et al., J. Biol. Chem, 272: 73	381-7389 (1997)		
	117	Jean et al., Toxicol. Lett., 95: 155-1	63 (1998)		
	118	Jenner & Timbrell, Arch. Toxicol.,	<b>68</b> : 349-357 (1994)		
	119	Johnston & Kroening, Pharmacol.	Toxicol., 83: 231-239 (1998)		
	120	Jover et al., Toxic. in Vitro., 6: 47-5	52 (1992)		
	121	Kanaji et al., J. Cell Biol., 151: 277	-288 (2000)		
	122	Kannan et al., Oncogene., 20: 2225	-2234 (2001)		. 12 =
	123	Karam & Ghanayem, Carcinogenes	sis, <b>18</b> : 2077-2083 (1997)		
	124	Kasper & Mueller, Carcinogenesis,	, 17: 2271-2274 (1996)		
	125	Kesterson et al., Hepatology, 4: 114	43-1152 (1984)		
	126	Kim & Ziegler, Drug Metab. Dispo	s., <b>28</b> : 1003-1006 (2000)		
	127	Kim et al., Drug Metab. Dispos., 26	<b>6</b> : 66-72 (1998)		
	128	Kim et al., Toxicol. Appl. Pharmace	ol., 102: 34-39 (1990)		
	129	Kinbara et al., Scand. J. Gastroente	erol., <b>32</b> : 947-952 (1997)		

NEOR	ATIO:	N DISCLOSURE CITATION	Attorney Docket	Application No.
Idau	<i></i>		44921-5038	09/917,800
	•	veral sheets if necessary) PTO Form 1449	Applicant: Donna MEND Filing Date: July 31, 2001	
- · · · · · · · ·				Group Art Onit. 40-50 1631
m	130	Kingsley et al., Epilepsia, 21: 699-7	/04 (1980)	(ABSTRACT ONLY)
	131	Kingsley et al., J. Clin. Pharmacol.	, <b>23</b> : 178-185 (1983)	
	132	Knapp et al., Am. J. Vet. Res., 56: 8	301-805 (1995)	_
	133	Koga et al., Fukuoka Igaku Zasshi,	<b>82</b> : 197-206 (1991)	
	134	Kondo et al., Cancer Res., 50: 6222	2-6228 (1990)	
	135	Kongo et al., Toxicol. Lett., 105: 10	03-110 (1999)	
	136	Koopen et al., Hepatology 27: 537-	545 (1998)	
	137	Koopen et al., J. Lipid. Res., 40: 10	0-108 (1999)	
	138	Kossor et al., Biochem. Pharmacol.	, 46: 2061-2066 (1993)	
	139	Kossor et al., Fundam. Appl. Toxico	ol., <b>26</b> : 51-62 (1995)	
	140	Kossor et al., Toxicol. Appl. Pharm	acol., <b>119</b> : 108-114 (1993)	
	141	Kretz-Rommel & Boelsterli, Toxico	ol. Appl. Pharmacol., <b>120</b> : 15	5-161 (1993)
	142	Kwak et al., Mol. Med., 7: 135-145	(2001)	
	143	Lake et al., Toxicology., 131: 9-20	(1998)	
	144	Lake, Annu. Rev. Pharmacol. Toxic	col., <b>35</b> : 483-507 (1995).	
	145	Larsen & Jefcoate, Arch. Biochem.		5)
	146	Laskin et al., Hepatology, 21: 1045	-1050 (1995)	
	147	Lauredo et al., J. Appl. Physiol., 85	: 2298-2304 (1998)	
	148	Lazartigues et al., Eur. J. Pharmace	ol., <b>361</b> : 61-71 (1998)	
	149	Lee et al., J. Pharm. Pharmacol., 5.	<b>2</b> : 341-355 (2000)	
	150	Lewis et al., Hepatology, 2: 870-87		
	151	Liang et al., Zhonghua Gan Zang B	Ring Za Zhi, 7: 72-73 (1999)	
	152	Liu et al., Infect. Immun., 66: 5089-	-5098 (1998)	<b>\</b>

AUG 2 1 2002 2

## RECEIVED AUG 2 2 2007 of 13

MOLEN	AATIO	N DISCLOSURE CITATION	Attorney Docket	Application ENTER 1600/2900		
(Use several sheets if necessary)		ward chasts if necessary	44921-5038 Applicant: Donna MENDR	07/717,000		
PTO Form 1449			Filing Date: July 31, 2001	Group Art Unit: 1645   631		
<i>1</i> 01	153	Liu et al., Mol. Cell. Biol., 20: 6105		(ABSTRACT ONLY)		
an	454			(ABS 114101 0/0-4)		
	154	Liu et al., Proc. Natl. Acad. Sci. U.	S.A, <b>98</b> : 6192-6197 (2001)			
	155	Liu et al., SHOCK, 14: 361-365 (20	000)			
	156	Lock et al., Toxicol. Lett., 10: 427-4	435 (1982)			
	157	Lorenzini et al., Carcinogenesis, 17	7: 1323-1329 (1996)			
	158	Lovett, Science, 289: 536-537 (200	0)			
	159	Lugovskoy et al., Cell, 99: 747-755	5 (1999)			
	160	Lullmann & Lullmann-Rauch, Toxi	icol. Appl. Pharmacol., 61: 138	-146 (1981)		
	161	Mann, Toxicol. Pathol., 25: 72-79 (	(1997)			
	162	Manoukian & Carson, <i>Drug Saf.</i> , <b>15</b> : 64-71 (1996)				
	163	Martelli et al., Carcinogenesis, 16: 1265-1269 (1995)				
	164	Masubuchi et al., J. Pharmacol. Ex	p. Ther., <b>287</b> : 208-213 (1998)			
	165	Masubuchi et al., J. Pharmacol. Ex	· · · · · · · · · · · · · · · · · · ·			
	166	Mayeux & Sano, N. Engl. J. Med.,	•			
	167					
		Mayol et al., Carcinogenesis., 13: 2				
	168	Maziasz et al., Toxicol. Appl. Phari	<del></del>			
	169	McKillop et al., Xenobiotica., 28: 4	165-478 (1998)			
	170	Menegazzi et al., Hepatology, 25: 5	585-592 (1997)			
	171	Metz & Ritter, J. Biol. Chem., 237:	5607-5614 (1998)			
	172	Metz et al., Mol. Pharmacol., 58: 3	19-327 (2000)			
	173	Milam and Byard, Toxicol. Appl. P.	harmacol., <b>79</b> : 342-347 (1985)			
	174	Minamide et al., J. Pharm. Sci., 87	: 640-646 (1998)			
	175	Mitchell & Acosta, J. Toxicol. Envi	iron. Health, 7: 83-92 (1981)			

OIPE OF 21 TOTAL DEPT.



AUG 2 2 2002

NEOD MATION DISCLOSURE CITATION			Attorney Docket 44921-5038	TECHOENT SHIP (09/917)
	•	veral sheets if necessary)	Applicant: Donna MENDR	
		PTO Form 1449	Filing Date: July 31, 2001	Group Art Unit: 1645   63
Cox	176	Mitchell et al., Ann. Intern. Med., 8	4: 181-192 (1976)	ABSTRACT ONLY
	177	Monteith et al., Drug Chem. Toxico	d., <b>19</b> : 71-84 (1996)	
	178	Moore et al., Fundam. Appl. Toxico	ol., <b>3</b> : 560-568 (1983)	
	179	Moran et al., Immunopharmacology	v, <b>12</b> : 245-250 (1986)	
	180	Morigasaki et al., Biochem. Biophy.	s. Res. Commun., 273: 261-26	6 (2000)
	181	Morooka et al., J. Biol. Chem, 270	: 30084-30092 (1995)	
	182	Motoki et al., Cancer Lett., 135: 14	5-150 (1999)	
	183	Nicholls-Grzemski et al., Toxicol. S	Sci., <b>56</b> : 220-228 (2000)	
	184	Nims et al., Carcinogenesis., 8: 67-	71 (1987)	
	185	Nordberg & Svensson, Drug Saf., 1	9: 465-480 (1998)	
	186	Nuwaysir et al., Mol. Carcinog., 24	: 153-159 (1999)	
	187	Oberhammer et al., Hepatology, 23	: 329-337 (1996)	
	188	Ohta et al., Biochem. J., 324: 777-7	82 (1997)	
	189	Omiecinski et al., Mol. Pharmacol.	, <b>38</b> : 462-470 (1990)	
	190	Omogbai et al., Drug Chem. Toxico	ol., <b>22</b> : 629-242 (1999)	
	191	Ono et al., Chem. Pharm. Bull. (Toi	· · · · · · · · · · · · · · · · · · ·	
	192	Ono et al., Chem. Pharm. Bull. (Tol		
	193	Orsler et at., Toxicol. Sci., 47: 203-2	210 (1999)	
	194	Outinen et al., Blood, 94: 959-967 (	· · · · · · · · · · · · · · · · · · ·	
	195		<u> </u>	
	196	Park & Pirmohamed, Toxicol. Lett.,		
	197	Park et al., Pharmacol. Ther., 68: 3	85-424 (1995)	



## RECEIVED

AUG 2 2 2002

<u>ن</u> ک. ح				Page 19 of 13
		N DISCLOSURE CITATION	Attorney Docket 44921-5038	A 向
(	(Use several sheets if necessary)		Applicant: Donna MENDR	
	]	PTO Form 1449	Filing Date: July 31, 2001	Group Art Unit:-1645 [63]
al	199	Pennie et al., Toxicol. Lett., 120: 35	3-358 (2001)	(ABSTRACT ONLY)
	200	Pennie et al., Toxicol. Sci. 54: 277-2	283 (2000)	
	201	Pennie, Toxicol. Lett., 112-113: 473	3-477 (2000)	
	202	Perrone et al., Toxicol. Appl. Pharm	nacol., <b>150</b> : 277-286 (1998)	
	203	Pischedda et al., Proc. Natl. Acad. S	Sci. U.S.A., <b>92</b> : 3511-3515 (199	95)
	204	Pohl et al., Arthritis Rheum., 37: 15	57 (1994)	
	205	Pollenz et al., Toxicol. Sci., 42: 117	-128 (1998)	
	206	Poyet & Labrie, Mol. Cell. Endocri	nol., <b>42</b> : 283-288 (1985)	
	207	Prevot et al. J. Biol. Chem, 276: 90	640-9648 (2001)	
	208	Pumford et al., Drug Metab. Rev., 2	<b>29</b> : 39-57 (1997)	
	209	Ratanasavanh et al., Xenobiotica., 1	<b>8</b> : 765-771 (1988)	
	210	Ray & Jena, Arch. Toxicol., 73: 594	-606 (2000)	
	211	Raymond et al., J. Toxicol. Environ	. Health, <b>51</b> : 463-476 (1997)	
	212	Reilly et al., Biochem. Biophys. Res	. Commun., 282: 321-328 (200	)1)
	213	Reuter et al., Life Sci., 55: 1-8 (1994)	4)	
	214	Rice et al., Carcinogenesis., 15: 39:	5-402 (1994)	
	215	Rich et al., Nature, 407: 777-783 (2	2000)	
	216	Riekkinen et al., Eur. J. Pharmacol	., <b>322</b> : 1-9 (1997)	
	217	Riekkinen et al., Eur. J. Pharmacol	., 323: 11-19 (1997)	
	218	Riendeau et al., Br. J. Pharmacol.,	<b>121</b> : 105-117 (1997)	
	219	Rininger et al., Biochem. Pharmaco	ol., <b>52</b> : 1749-1755 (1996)	
	220	Rininger et al., Drug Discov. Today	y, <b>5</b> : 560-568 (2000)	
	221	Roberts et al., Toxicol. Appl. Pharm	nacol., 135: 192-199 (1995)	

/	Ó1	P	E	7	
PA	AUG	2	1 7	TES.	FEIGE

TOFOR	ATIO	N DISCLOSURE CITATION	Attorney Docket 44921-5038	Application No. <b>09/917,800</b>
(Use several sheets if necessary) PTO Form 1449			Applicant: Donna MENDRI	CK et al.
			Filing Date: July 31, 2001	Group Art Unit: 1631
ar	222	Rockett & Dix, Environ. Health Pe	rspect., 107: 681-685 (1999)	(ABSTRACT only)
	223	Rodrigues & Machinist, Toxicol. Ap	ppl. Pharmacol., <b>137</b> : 193-201 (	1996)
	224	Ruepp et al., Toxicol. Sci., 65: 135-	150 (2002)	
	225	Runge-Morris et al., Drug Metab. I	Dispos., <b>26</b> : 795-801 (1998)	
	226	Sachidanandam et al., Nature, 409:	928-933 (2001)	
	227	Safe, Annu. Rev. Pharmacol. Toxico	ol., <b>38</b> : 121-158 (1998)	
	228	Scales & Timbrell, J. Toxicol. Envi		
	229	Scali et al., Pharmacol. Res., 36: 46		
	230	Schiller et al., Toxicol. Appl. Pharn		
	231	Schiodt et al., N. Engl. J. Med., 337		
	232	Scholer et al., Am. J. Med., 80: 34-3		
	233	Schulte-Hermann et al., Cancer Re.		
	234	Seefeld et al., Arch. Environ. Conto		
-	235	Servais & Galand, Cell Biol. Int Re		
	237	Shannon et al., J. Pharmacol. Exp.		
	238	Sidhu et al., Arch. Biochem. Biophy		
	239	Sinz & Woolf, Biochem. Pharmaco	<u> </u>	
	240	Skouteris and McMenamin, <i>Bioche</i> Skrtic <i>et al.</i> , <i>J. Hepatol.</i> , <b>27</b> : 903-93		
	241	Smith, Trends Pharmacol. Sci., 22:		
	242	Snape et al., Neuropharmacology, 3		
	243	Somani & Dube, Int. J. Clin. Pharm		87 (1989)
	244	Somani, Biopharm. Drug Dispos.,		
		Joinam, biopharm. Drug Dispos.,	10. 107-203 (1707)	<u> </u>

/-	OIPE	· 46
/	Wile 5 1 5	EGE STE
PACA	~ INFQ	BMAT

INFORM	INFORMATION DISCLOSURE CITATION		Attorney Docket 44921-5038	Application No. <b>09/917,800</b>
	(Use se	veral sheets if necessary)	Applicant: Donna MENDR	UCK et al.
		PTO Form 1449	Filing Date: July 31, 2001	Group Art Unit: 4645 [63]
Soni et al., Regul. Toxicol. Pharma		Soni et al., Regul. Toxicol. Pharma	col., <b>29</b> : 165-174 (1999)	Group Art Unit: #645 [63] (ABSTRACT ONLY)
T	246	Stachlewitz et al., J. Pharmacol. Ex	cp. Ther., <b>282</b> : 1591-1599 (199	97)
	247	Stohs et al., Biochem. Biophys. Res.	. Commun., 111:854-859 (198.	3)
	248	Tanaka et al., Clin. Exp. Pharmaco	l. Physiol., <b>20</b> : 543-547 (1993)	)
	249	Tarloff et al., Fundam. Appl. Toxico	ol., <b>30</b> : 13-22 (1996)	
	250	Tenniswood et al., Mol. Cell. Endoc	crinol., 37: 153-158 (1984)	
	251	Timbrell et al., J. Pharmacol. Exp.	Ther., <b>213</b> : 364-369 (1980)	
	252	Timbrell et al., J. Toxicol. Environ.	Health, 10: 955-968 (1982)	
	253	Timbrell, Arch. Toxicol. Suppl., 2:	1-8 (1979)	
	254	Tournier et al., Lab. Invest., 59: 657	7-665 (1988)	
	255	Trauner et al., N. Engl. J. Med., 339	9: 1217-1227 (1998)	
	256	Tucker et al., Fundam. Appl. Toxico	ol., <b>3</b> : 579-586 (1983)	
	257	Tucker, Am. J. Med., 73: 27-30 (198	82)	
	258	Tygstrup et al., J. Hepatol., 25: 183	-190 (1996)	
	259	Tygstrup et al., J. Hepatol., 27: 156	-162 (1997)	
	260	van Gijssel et al., Carcinogenesis, 1	<b>18</b> : 1027-1033 (1997)	
	261	Vance et al., Epilepsia, 35: 1016-10	)22 (1994)	
	262	Visen et al., J. Pharmacol. Toxicol.	Methods, 40: 173-179 (1998)	
	263	Wan et al., Infect. Immun., 63: 2435	5-2442 (1995)	
	264	Wang & Dickinson, Drug Metab. D	Dispos., <b>26</b> : 98-104 (1998)	
	265	Wang et al., Neuroreport., 10: 789-	793 (1999)	
	266	Waring & Ulrich, Annu. Rev. Pharm	nacol. Toxicol., 40: 335-352 (2	2000
	267	Waring et al., Toxicol. Appl. Pharm	pacol., 175: 28-42 (2001)	

AUG 2 1 2002

Page 13 of 13

TATOMEN	ATIO	N DISCLOSURE CITATION	Attorney Docket 44921-5038	Application No. 09/917,800
	(Use se	veral sheets if necessary)	Applicant: Donna MENDRIC	
	PTO Form 1449		Filing Date: July 31, 2001	Group Art Unit: 1645 1631
an.	268	Waring et al., Toxicol. Lett., 120: 35	59-368 (2001)	(ABSTRACT only)
1	269	Waterfield et al., Biochem. Pharmac	col., <b>46</b> : 589-595 (1993)	
	270	Weber et al., Fundam. Appl. Toxico.	l., <b>21</b> : 523-534 (1993)	
	271	Weber et al., Toxicology, 66: 133-14	44 (1991)	
	272	Werner et al., Mutat. Res., 395: 179	-187 (1997)	
	273	White et al., Biochem. Pharmacol.,	<b>45</b> : 21-30 (1993)	
	274	White et al., Carcinogenesis, 13: 21	97-2203 (1992)	
	275	Wiesenberg-Boettcher et al., Drugs	Exp. Clin. Res., 15: 501-509 (198	39)
	276	Woodward & Timbrell, Toxicology.	, 30: 65-74 (1984)	
	277	Woolf et al., Drug Metab. Dispos.,	21: 874-882 (1993)	
	278	Yata et al., J. Hepatol., 30: 419-424	(1999)	
	279	Zarif et al., Inflammation, 20: 217-2	27 (1996)	
	280	Zhao et al., J. Biol. Chem, 276: 27-	432-27440 (2001)	
	281	Zhou et al., J. Clin. Invest., 108: 116	67-1174 (2001)	
Examiner		Muy	Date Considered	128/03
Examiner:	thre	tial if reference considered, whether ough citation if not in conformance mmunication to applicant.		

Application No. INFORMATION DISCLOSURE CITATION Attorney Docket 09/917,800 44921-5038 Applicant: Donna MENDRICK et al. (Use several sheets if necessary) PTO Form 1449 Filing Date: July 31, 2001 Group Art Unit: 1645 1631 U.S. PATENT DOCUMENTS Filing Date **Issue Date** Name Class Sub-Initial Patent No. class FOREIGN PATENT DOCUMENTS Translation Document No. **Publication Date Country** Class Subclass Yes RECEIVED SEP 1 0 2002 TECH CENTER 1600/2900 OTHER DOCUMENTS ABSTRACT ONLY) 1. COL Abernathy et al., Proc. Soc. Exp. Biol. Med., 199: 54-58 (1992) 2. Accatino et al., Hepatology, 28: 129-140 (1998) 3. Agha & Gad, Pharmacol. Res., 32: 279-285 (1995) 4. Akesson & Akesson, Scand. J. Rheumatol., 13: 198-202 (1984) 5. al Casey et al., Toxicol. Lett., 76: 257-265 (1995) 6. Ammann et al., Toxicol. Appl. Pharmacol., 149: 217-225 (1998) 7. Andersson et al., Toxicology, 135: 11-20 (1999) 8. Anton et al., Cell Biochem. Biophys., 32: 27-36 (2000) 9. Ashby & Lefevre, J. Appl. Toxicol., 20: 35-47 (2000) 10. Aura et al., Eur. J. Pharmacol., 342: 15-20 (1998) 11. Ax et al., Biochem. Pharmacol., 59: 293-300 (2000) 12. Azri-Meehan et al., Fundam. Appl. Toxicol., 22: 172-177 (1994) 13. Bagetta et al., Eur. J. Pharmacol., 213: 301-304 (1992) 14. Basnet et al., Biol. Pharm. Bull., 19: 1479-1484 (1996) 15. Becker et al., Am. J. Kidney Dis., 22: 611-615 (1993) 16. Becquemont et al., Fundam. Clin. Pharmacol., 10: 156-157 (1996) 17. Becquemont et al., Pharmacogenetics, 7: 251-253 (1997)

INFORMATION DISCLOSURE CITATION		•	Attorney Docket 44921-5038	Application <b>09/917,800</b>	No.
	(Use s	everal sheets if necessary)	Applicant: Donna MENDR		
-	T	PTO Form 1449	Filing Date: July 31, 2001		Init: 1645 1631
CAL	18.	Belles et al., Vet. Hum. Toxicol., 40	: 269-272 (1998)	LABSTRACT	ONLY
	19.	Benoit et al., Biochem. Pharmacol.,	53: 423-427 (1997)		
	20.	Bentley et al., Food Chem. Toxicol.	, 31: 857-907 (1993)		
	21.	Bergeron et al., Xenobiotica, 28: 30	3-312 (1998)		
	22.	Bergstrom et al., Annu. Rev. Microb	biol., <b>49</b> : 607-639 (1995)		
	23.	Berson et al., Gastroenterology, 110	<b>0</b> : 1878-1890 (1996)		
	24.	Berthou et al., Eur. J. Biochem., 232	<b>2</b> : 179-187 (1995)		
	25.	Bezek et al., Xenobiotica, 26: 935-9	946 (1996)		
	26.	Bhagwat et al., Int. J. Oncol., 13: 28	81-288 (1998)		
	27.	Blackard et al., J. Clin. Gastroenter	ol., <b>26</b> : 57-59 (1998)		
	28.	Blazka et al., J. Inflamm., 47: 138-1	50 (1995-96)		
	29.	Blazka et al., Res. Commun. Mol. P.	athol. Pharmacol., <b>92</b> : 259-27	3 (1996)	
	30.	Blazka et al., Toxicol. Appl. Pharma	acol., 133: 43-52 (1995)		
	31.	Bombick & Matsumura, J. Biochem	n. Toxicol., 2: 141-154 (1987)		
	32.	Booth et al., Hepatology, 23: 771-78	80 (1996)		
	33.	Bort et al., Drug Metab. Dispos., 24	I: 969-975 (1996)		
	34.	Brown et al., Arch. Biochem. Biophy	ys., <b>342</b> : 134-142 (1997)		
	35.	Brown et al., Environ. Health Persp	pect., 104: 634-6440 (1996)		1
	36.	Bruckner et al., J. Pharmacol. Exp.	Ther., 300: 273-281 (2002)		
	37.	Bulera et al., Toxicol. Appl. Pharma	acol., <b>134</b> : 313-320 (1995)	J	
	38.	Burcham & Harman, J. Biol. Chem.	, <b>266</b> : 5049-5054 (1991)		1
	39.	Burczynski & Penning, Cancer Res.	., <b>60</b> : 908-915 (2000)		
	40.	Bursch et al., Arch. Toxicol., 59: 22	1-227 (1986)		
	41.	Buttery et al., Lab. Invest., 71: 755-	764 (1994)		
	42.	Byard & Dougherty, In Vitro Cell D	Dev. Biol., <b>21</b> : 489-494 (1985)		
	43.	Cabre et al., Clin. Exp. Pharmacol.	Physiol., <b>27</b> : 694-699 (2000)		
	44.	Calabrese et al., Food Chem. Toxico			
	45.	Carfagna et al., Toxicol. Appl. Phari	<u></u>		1
	46.	Carpenter-Deyo & Reed, J. Pharma		(1991)	
	47.	Carriero et al., Pharmacol. Biochem		<u> </u>	
	48.	Casley et al., Pharmacogenetics, 7:			

INFORMATION DISCLOSURE CITATION		ON DISCLOSURE CITATION	Attorney Docket 44921-5038	Application No. <b>09/917,800</b>
	(Use s	several sheets if necessary)	Applicant: Donna MENDRIC	K et al.
		PTO Form 1449	Filing Date: July 31, 2001	Group Art Unit: 1645 1631
on	49.	Cattley et al., Cancer Lett., 33: 269	-277 (1986)	(ABSTRACT ONLY)
	50.	Cattley et al., Carcinogenesis, 9: 11	79-1183 (1988)	
	51.	Chen et al., Amino Acids, 18: 319-3	27 (2000)	
	52.	Chen et al., Carcinogenesis, 21: 120	05-1211 (2000)	
	53.	Chen et al., J. Environ. Pathol. Tox	icol. Oncol., 14: 83-99 (1995)	
	54.	Cheng et al., Neuroreport., 8: 97-10	)1 (1996)	
	55.	Chico et al., Exp. Clin. Endocrinol.	Diabets., 104: 137-144 (1996)	
	56.	Corton et al., Biochimie., 79: 151-1	62 (1997)	
	57.	Cousins et al., Eur. J. Pharmacol.,	<b>322</b> : 137-145 (1997)	
	58.	Cousins et al., Physiol. Behav., 64:	153-158 (1998)	
	59.	Coyne et al., Gastroentology, 75: 76	6-90 (1978)	
	60.	Crismon, Ann. Pharmacother., 28:	744-751 (1994)	
	61.	Cuevas et al., Clin. Exp. Pharmacol	l. Physiol., 28: 637-642 (2001)	
	62.	Darbre & King, J. Steriod Biochem.	., 36: 385-390 (1990)	
	63.	Davila et al., Toxicology., 57: 267-2	286 (1989)	
	64.	Davis et al., Biochemistry, 25: 1632	2-1636 (1986)	
	65.	Davydov, Trends Biochem. Sci., 26	: 155-1560 (2001)	
	66.	De Ferrari et al., J. Neurosci. Res.,	<b>52</b> : 435-444 (1998)	
	67.	Delaney & Segel, South. Med. J., 78	<b>8</b> : 1390-1392 (1985)	
	68.	DeLeve et al., Biochem. Pharmacol	<i>l.</i> , <b>53</b> : 1339-1345 (1997)	
	69.	DeNoble et al., Pharmacol. Biocher	m. Behav., 36: 957-961 (1990)	
	70.	Dilworth et al., Toxicol. In Vitro, 4:	169-176 (2000)	
	71.	Dirven et al., Biochem. Pharmacol.	, 43: 261-299 (1992)	
	72.	Eri & Tveter, Eur. Urol., 26: 219-22	26 (1994)	
	73.	Farghali et al., Int. J. Immunopharn	nacol., <b>19</b> : 599-604 (1997)	
	74.	Farghali et al., Methods Find. Exp.	Clin. Pharmacol., <b>6</b> : 449-454 (19	084)
	75.	Fariss et al., Hepatology, 20: 240-2	46 (1994)	
	76.	Fernandez-Salguero & Gonzalez, P	harmacogenetics, 5: S123-128 (	(1995)
	77.	Forestier et al., Biochem. Biophys. I	Res. Commun., 225: 377-383 (199	96)
	78.	Friedman et al., Dig. Dis. Sci., 44: 1	1362-1363 (1999)	
	79.	Fritz & Kaina, Biochem. Biophys. R	Res. Commun., <b>268</b> : 784-789 (200	00)

INFOR	RMATIO	N DISCLOSURE CITATION	Attorney Docket 44921-5038	Application No. <b>09/917,800</b>	
	(Use so	everal sheets if necessary)	Applicant: Donna MENDRICK		
	-	PTO Form 1449	Filing Date: July 31, 2001	Group Art Unit: 1	
COL	80.	Fujiki, FEBS Lett., 476: 42-46 (2000)	0)	(ABSTRACT	ONTL)
	81.	Galisteo et al., J. Pharmacol. Exp. 1	Ther., <b>294</b> : 160-167 (2000)		<u>-</u>
	82.	Gall et al., J. Steroid Biochem. Mol.	Biol., 70: 101-108 (1999)		
	83.	Galli & Mori, Arch. Toxicol., 65: 33	30-334 (1991)		
	84.	Garcia-Allan et al., Arch. Toxicol.,	71: 409-415 (1997)		
	85.	Gebhardt et al., Cell. Biol. Toxicol.,	<b>12</b> : 57-68 (1996)		
	86.	Geiger et al., Agents Actions, 38: Sp	pec No: C69-72 (1993)		
	87.	Ghatineh & Timbrell, Biochem. Soc	e. Trans., 18: 1217-1218 (1990)		
	88.	Giacobini et al., Neuropharmacolog	zy, <b>35</b> : 205-211 (1996)		
	89.	Giacobini, Neurochem. Int., 32: 413	-419 (1998)		
	90.	Gil et al., Biochim. Biophys. Acta.,	<b>1272</b> : 140-146 (1995)		
	91.	Gomez-Lechon et al., Altern. Lab. A	Anim., 29: 225-231 (2001)		_
	92.	Gong et al., Pharmacogenetics, 11:	357-368 (2001)		
	93.	Gracon et al., Alzheimer Dis. Assoc.	. Disord., 12: 93-101 (1998)		
	94.	Guarner et al., Liver, 5: 35-39 (1985)	5)		
	95.	Gupta et al., Carcinogenesis, 6: 933	3-936 (1985)		
	96.	Gupta et al., Toxicol. Appl. Pharma	col., <b>146</b> : 317-327 (1997)		
	97.	Ha et al., Biochem. Mol. Biol. Int., 2	<b>29</b> : 387-393 (1993)		
	98.	Hakansson, Acta Neurol. Scand. Sup	ppl., <b>149</b> : 7-9 (1993)		
	99.	Hallak & Giacobini, Neuropharmac	cology, <b>26</b> : 521-530 (1987)		
	100.	Hanson et al., Lab. Invest., 41: 500-	503 (1979)		
	101.	Hartung et al., Dev. Biol. Stand., 86	: 85-96 (1996)		
	102.	Hase et al., Planta Med., 63: 22-26	(1997)		
	103.	Hassett et al., Biochem. Pharmacol.	, 55: 1059-1069 (1998)		
	104.	Hayashi et al., Biochim. Biophys. Ac	cta., 879: 140-148 (1986)		
	105.	Henderson et al., Proc. Natl. Acad.	Sci. U.S.A., 97: 12741-12745 (200	0)	
	106.	Herbst et al., Am. J. Pathol., 150: 10	647-1659 (1997)		
	107.	Hildebrand et al., Arch. Toxicol., 73	3: 233-245 (1999)		
	108.	Hill & Roth, Toxicol. Appl. Pharma	acol., <b>148</b> : 169-175 (1998)		
	109.	Hill et al., Toxicol. Sci., 47: 118-125	5 (1999)		
	110.	Hinz et al., Neurochem. Res., 21: 33	31-337 (1996)		

INFORMATION DISCLOSURE CITATION		ON DISCLOSURE CITATION	Attorney Docket 44921-5038	Application No. 09/917,800
	(Use se	everal sheets if necessary)	Applicant: Donna MENDRIC	
		PTO Form 1449	Filing Date: July 31, 2001	Group Art Unit: 1645 1631
ar	111.	Hoebe et al., Vet. Q., 22: 21-25 (200	00)	(ABSTRACT ONLY)
	112.	Hoshi & Fujino, Chem. Pharm. Bull	<i>l.</i> , <b>38</b> : 3446-3448 (1990)	
	113.	Hoshi et al., Jpn. J. Pharmacol., 50:	: 289-293 (1989)	
	114.	Hussain et al., Sci. Total. Environ.,	<b>274</b> : 151-160 (2001)	
	115.	Ibebunjo et al., Can. J. Anaesth., 44	: 1021-1026 (1997)	
	116.	Iimuro et al., J. Leukoc. Biol., 55: 72	23-728 (1994)	
	117.	James & Roberts, Carcinogenesis, 1	17:1623-32 (1996)	
	118.	Jeon et al., Toxicol. Appl. Pharmaco	ol., <b>144</b> : 27-35 (1997)	
	119.	Jinno, et al., Arch. Toxicol., 71: 550	-555 (1997)	
	120.	Jover et al., Biochem. Pharmacol., 4	<b>46</b> : 1967-1974 (1993)	
	121.	Jurima-Romet & Huang, Biochem. I	Pharmacol., <b>46</b> : 2163-2170 (199	3)
	122.	Kaminski & Stevens, Toxicology, 75	<b>5</b> : 175-188 (1992)	
	123.	Karchner et al., Mar. Environ. Res.,	<b>50</b> : 51-56 (2000)	
	124.	Kasper & Mueller, Carcinogenesis,	<b>20</b> : 2185-2188 (1999)	
	125.	Kato & Yamazoe et al., Toxicol. Let	tt., <b>64-65</b> : 661-667 (1992)	
	126.	Kaufmann et al., Carcinogenesis, 9:	: 779-782 (1988)	
	127.	Kawai et al., Infect. Immun., 59: 256	60-2566 (1991)	
	128.	Keller et al., Toxicol. Appl. Pharma	col., <b>104</b> : 259-266 (1990)	
	129.	Kemper, Prog. Nucleic Acid Res. M	Tol. Biol., 61: 23-64 (1998)	
	130.	King & Somani, Life Sci., 41: 2007-	-2015 (1987)	
	131.	Kishi et al., Mol. Aspects Med., 18:	S71-S77 (1997)	
	132.	Kitteringham et al., Hepatology, 32:	: 321-333 (2000)	
	133.	Knight et al., Toxicol. Sci., 62: 212-	220 (2001)	
	134.	Kobayashi et al., Drug Metab. Disp	os., <b>26</b> : 1026-1030 (1998)	
	135.	Kocaoglu et al., Arch. Immunol. The	er. Exp. (Warsz), <b>45</b> : 73-77 (199	7)
	136.	Kocarek et al., Mol. Pharmacol., 54	: 474-84 (1998)	
	137.	Krall et al., Ann. Pharmacother., 33	: 441-450 (1999)	
	138.	Kryger et al., Structure Fold. Des.,	7: 297-307 (1999)	
	139.	Kullak-Ublick & Meier, Clin. Liver	Dis., 4: 357-385 (2000)	
	140.	Kunstle et al., Immunol. Lett., 55: 5-	-10 (1997)	
	141.	Kuo et al., J. Pharmacol. Exp. Ther.	., <b>282</b> : 1072-1083 (1997)	

INFORMATION DISCLOSURE CITATION		N DISCLOSURE CITATION	Attorney Docket 44921-5038	Application No. 09/917,800	
	(Use se	everal sheets if necessary)	Applicant: Donna MENDRICK		
	1	PTO Form 1449	Filing Date: July 31, 2001	Group Art Unit: 1645	
or	142.	Lacroix et al., Gene, 86: 201-207 (1	990)	(ABSTRACT	W4/
	143.	Lagadic-Gossmann et al., Cell Biol.	Toxicol., 14: 361-373 (1998)		
	144.	Lahiri & Farlow, J. Mol. Neurosci.,	7: 41-49 (1996)		
	145.	Lake et al., Environ. Health Perspec	ct., <b>67</b> : 283-290 (1986)		
	146.	Lamb et al., Toxicol. Appl. Pharmac	col., <b>101</b> : 106-113 (1989)		
	147.	Lang et al., Alcohol Clin. Exp. Res.,	<b>22</b> : 823-829 (1998)		
	148.	Larrauri et al., Mol. Toxicol., 1: 301	-311 (1987-1988)		
	149.	Laurent & Fraser, FASEB J., 6: 239	7-2404 (1992)		
	150.	Lees et al., Lipids, 30: 221-226 (199	95)		
	151.	Lemberger et al., J. Biol. Chem., 27	1: 1764-1769 (1996)		
	152.	Lèullmann-Rauch & Scheid, Vircho	ows Arch. B Cell Pathol., 19: 255-2	68 (1975)	
	153.	Li et al., Biochem. Biophys. Res. Co	ommun., <b>229</b> : 982-999 (1996)		·-
	154.	Li et al., Zhonghua Gan Zang Bing	Za Zhi, 9: 103-104 (2001)		
	155.	Lin et al., Chem. Res. Toxicol., 9: 1	183-1193 (1996)		
	156.	Liu et al., Biol. Pharm. Bull., 21: 44	1-49 (1998)		
	157.	Liu et al., Cancer Res., 52: 4139-41	43 (1992)		
	158.	Lomri et al., Chem. Res. Toxicol., 6	: 800-807 (1993)		
	159.	Lupo et al., Toxicology., 44: 229-23	9 (1987)		· · · · · · · · · · · · · · · · · ·
	160.	M'Harzi et al., Pharmacol. Biochen	n. Behav., <b>56</b> : 663-668 (1997)		
	161.	Mahnke et al., Arch. Biochem. Biop	hys., <b>337</b> : 62-68 (1997)		
	162.	Mancy et al., Biochemistry, 38: 142	64-14270 (1999)		
	163.	Marsman et al., Toxicol. Appl. Phar	rmacol., 122: 1-6 (1993)		
	164.	Martelli et al., J. Pharmacol. Exp. T	Ther., <b>273</b> : 113-120 (1995)		
	165.	Martelli et al., Mutagenesis, 14: 463	3-472 (1999)		
	166.	Matsuda et al., Bioorg. Med. Chem.	Lett., 8: 2191-2196 (1998)		
	167.	Matsuo et al., Acta Med. Okayama,			
	168.	Mayorga et al., Pharmacol. Biochen	<u> </u>		
	169.	McGirr et al., Xenobiotica, 20: 933-			
	170.	McMartin et al., Res. Commun. Che	<del></del>	) (1981)	
_   _	171.	Mejdoubi et al., Biochem. Biophys.			
	172.	Meyers et al., J. Pharmacol. Exp. Ti			

INFORMATION DISCLOSURE CITATION		N DISCLOSURE CITATION	Attorney Docket 44921-5038	Application No. <b>09/917,800</b>	
	(Use se	everal sheets if necessary)	Applicant: Donna MENDRIC		
<u> </u>	1	PTO Form 1449	Filing Date: July 31, 2001	Group Art Unit: 4645	<del></del>
ca	173.	Migliari et al., Arch. Ital. Urol. And	<i>Irol.</i> , <b>71</b> : 293-302 (1999)	(ABSTRACT	DNLY
	174.	Miller et al., Toxicol. Sci., 48: 30-37	7 (1999)		
	175.	Mino et al., J. Histochem. Cytochen	n., <b>46</b> : 1151-1160 (1998)		
	176.	Mizutani & Miyamoto, Toxicol. Let	tt., <b>105</b> : 25-30 (1999)		
	177.	Mohammed et al., J. Neural. Transi	m. Park. Dis. Dement. Sect., 2: 2:	85-294 (1990)	
	178.	Monteith et al., Arch. Toxicol., 72:	147-156 (1998)		
	179.	Mus'ilkov'a & Tucek, Neurosci. Le	ett., <b>125</b> : 113-136 (1991)		
	180.	Nabeshima et al., Jpn. J. Pharmaco	<i>l.</i> , <b>57</b> : 311-319 (1991)		27.44
	181.	Nakamura & Lou, J. Biol. Chem., 2	<b>70</b> : 7347-7353 (1995)		
	182.	Neghab & Stacey, Chem. Biol. Inter	ract., 99: 179-192 (1996)		
	183.	Nochi et al., Biol. Pharm. Bull., 18:	1145-1147 (1995)		
	184.	Nussler et al., ALTEX, 18: 91-101 (	2001)		
	185.	O'Hara et al., Fundam. Appl. Toxic	ol., 13: 605-615 (1989)		
	186.	O'Hara et al., J. Appl. Toxicol., 11:	147-154 (1991)		
	187.	Ohuchi et al., Am. J. Physiol., 268 (	(6 Pt 1) G997-G1003 (1995)		
	188.	Olivier & Krisans, Biochim. Biophy	es. Acta, 1529: 89-102 (2000)		
	189.	Olsen et al., Chem. Biol. Interact., 1	<b>107</b> : 93-108 (1997)		
	190.	Olson et al., Fundam. Appl. Toxicol	l., <b>22</b> : 631-640 (1994)		
	191.	Ono et al., Biol. Pharm. Bull., 18: 1	779-1783 (1995)		
	192.	Padgham et al., Biochem. Biophys.	Res. Commun., <b>15</b> : 599-605 (199	93)	
	193.	Panduro et al., Nephron, 65: 100-10	7 (1993)		
	194.	Paoletti et al., Exp. Neurol., 149: 34	19-355 (1998)		
	195.	Paolini et al., Chem. Biol. Interact.,	<b>95</b> : 127-139 (1995)		
	196.	Parte et al., J. Androl., 21: 525-533	(2000)		
	197.	Parzefall et al., Carcinogenesis, 22:	519-523 (2001)		
	198.	Penzes et al., Gene, 191: 167-172 (	1997)		
	199.	Peruzzi et al., Neuroreport., 8: 103-	-108 (1996)		
	200.	Petrulis & Bunce, J. Biochem. Mol.	Toxicol., 14: 73-81 (2000)		<u> </u>
	201.	Phillips et al., Carcinogenesis, 17: 8	89-94 (1996)		
	202.	Plant et al., Carcinogenesis, 19: 925	5-931 (1998)		
	203.	Plymale & de la Iglesia, J. Appl. To	exicol., 19: 31-38 (1999)		

INFOR	INFORMATION DISCLOSURE CITATION		Attorney Docket 44921-5038	Application No. <b>09/917,800</b>		
	(Use se	everal sheets if necessary)	Applicant: Donna MENDRICK et al.			
·		PTO Form 1449	Filing Date: July 31, 2001	Group Art Unit: 1645 163		
cor	204.	Porubek et al., Drug Metab. Dispos., 17: 123-130 (1993) (ABSTRACT ONLY)				
	205.	Porubek et al., Mol. Pharmacol., 31	: 647-653 (1987)			
	206.	Preece et al., Arch. Toxicol., 64: 49-	53 (1990)			
	207.	Puri et al., Mutagenesis, 6: 471-478	(1991)			
	208.	Qi et al., Cell. Biochem. Biophys., 3	<b>2</b> : 187-204 (2000)			
	209.	Rabe et al., Drug Saf., 14: 25-38 (19	996)			
	210.	Riekkinen et al., Eur. J. Pharmacol.	, <b>366</b> : 13-18 (1999)			
	211.	Roberts et al., Toxicol. Lett., 112-11	3: 49-57 (2000)			
	212.	Roberts et al., Toxicol. Lett., 50: 283	3-288 (1990)			
	213.	Robertson et al., Arch. Toxicol., 72:	362-371 (1998)			
	214.	Rodi et al., Toxicol. Pathol., 27: 107	7-110 (1999)			
	215.	Roskams et al., Hepatology, 24: 524	4-532 (1996)			
	216.	Roskams et al., J. Pathol., 185: 290-	-297 (1998)			
	217.	Roy, J. Endocrinol., 70: 189-195 (19	976)			
	218.	Runge-Morris et al., Drug Metab. D	Dispos., <b>24</b> : 734-737 (1996)			
	219.	Runge-Morris, Chem. Biol. Interact.	., 3: 15-27 (1998)			
	220.	Rusyn et al., Carcinogenesis, 20: 20	95-2100 (1999)			
	221.	Sallustio & Holbrook, Drug Metab.	Dispos., 29: 1535-1538 (2001)			
	222.	Scassa et al., Exp. Cell Res., 244: 46	50-469 (1998)			
	223.	Schiaffonati & Tiberio, Liver, 17: 18	83-191 (1997)			
	224.	Schrenk et al., Arch. Toxicol., 65: 1	14-118 (1991)			
	225.	Seitz et al., Chem. Res. Toxicol., 11:	: 513-519 (1998)			
	226.	Seitz et al., Hepatology, 20: 487-493	3 (1994)			
	227.	Sendo et al., Chem. Pharm. Bull. (To	Yokyo), <b>32</b> : 795-796 (1984)			
	228.	Sèurmen & Eryèurek, Toxicology, 7	75: 63-69 (1992)			
	229.	Severson et al., Can. J. Physiol. Pha	armacol., <b>62</b> : 244-247 (1984)			
	230.	Shackleton et al., Toxicol. Appl. Pho	armacol., 130: 294-303 (1995)			
	231.	Shear et al., Skin Pharmacol., 8: 279	9-291 (1995)			
	232.	Shervington, Biochem. Mol. Biol. In				
	233.	Sheweita et al., Toxicology, 28: 217	-224 (2001)			
	234.	Shiota et al., Res. Commun. Mol. Pa		996)		

INFOR	MATIO	N DISCLOSURE CITATION	Attorney Docket 44921-5038	Application No. 09/917,800
	(Use se	everal sheets if necessary)	Applicant: Donna MENDRIC	
		PTO Form 1449	Filing Date: July 31, 2001	Group Art Unit:-1645   62/
con			<b>21</b> : 580-586 (1993)	(ABSTRACT ONLY)
	236.	Shultz et al., Toxicol. Appl. Pharma	acol., <b>154</b> : 84-96 (1999)	
	237.	Sidhu & Omiecinski, J. Biochem. M	fol. Toxicol., 13: 1-9 (1999)	
	238.	Sidhu & Omiecinski, J. Biol. Chem.	, 273: 4769-4775 (1998)	
	239.	Smith et al., J. Neurosci. Res., 66: 2	236-241 (2001)	
	240.	Smith et al., J. Pharmacol. Exp. The	er., <b>280</b> : 710-720 (1997)	
	241.	Styles et al., Carcinogenesis, 18: 30	03-313 (1997)	
	242.	Sundstrom et al., Biochem. Pharma	col., <b>37</b> : 1003-1008 (1988)	
	243.	Takeuchi et al., Neuropediatrics, 19	D: 158-161 (1988)	
	244.	Tamura et al., Toxicology, 63: 199-2	213 (1996)	
	245.	Tanaka et al., J. Physiol. Pharmaco	l., <b>50</b> : 405-417 (1999)	
	246.	Tang et al., Drug Metab. Dispos., 2	<b>7</b> : 365-372 (1999)	
	247.	Tansey & Shechter, Prog. Nucleic A	Acid Res. Mol. Biol., <b>75</b> : 157-195	5 (2001)
	248.	Tarbet et al., J. Biol. Chem., 266: 16	6667-16673 (1991)	
	249.	Tee et al., Toxicol. Appl. Pharmaco	l., <b>83</b> : 294-314 (1986)	
	250.	Theilig et al., J. Am. Soc. Nephrol.,	<b>12</b> : 2209-2220 (2001)	
	251.	Thomas et al., Oncogene, 19: 5259-	-5269 (2000)	
	252.	Timbrell & Waterfield, Adv. Exp. M	Med. Biol., 403: 125-134 (1996)	
	253.	Tithof et al., Environ. Health Persp	ect., 104:52-58 (1996)	
	254.	Titorenko & Rachubinski, Nat. Rev.	Mol. Cell. Biol., 2: 357-68 (200	01)
	255.	Tobin et al., Mol. Endocrinol., 14: 7	741-752 (2000)	
	256.	Tsokos-Kuhn, Arch. Biochem. Biop	hys., <b>265</b> : 415-424 (1988)	
	257.	Turnbull et al., Biochem. Pharmaco	ol., <b>32</b> : 1887-1892 (1983)	
	258.	Uhl et al., Mutat. Res., 468: 213-22:	5 (2000)	
	259.	Vaananen et al., Inflammation, 16: 2	227-240 (1992)	
	260.	Varone & Canepa, Arch. Biochem.	Biophys., <b>341</b> : 259-266 (1997)	
	261.	Villalobos et al., J. Med. Chem., 38	: 2802-2808 (1995)	
	262.	Vinggaard et al., Toxicol. Appl. Pha	armacol., <b>55</b> : 150-160 (1999)	
	263.	Vonen and Morland, Arch. Toxicol.		
	264.	Wagstaff & McTavish, Drugs Aging	g, 4: 51-540 (1994)	
	265.	Wang & Tang, Eur. J. Pharmacol.,	<u> </u>	

INFORMATION DISCLOSURE CITATION		N DISCLOSURE CITATION	Attorney Docket 44921-5038	Application No. <b>09/917,800</b>
	(Use se	everal sheets if necessary)	Applicant: Donna MENDRICK et al.	
PTO Form 1449		PTO Form 1449	Filing Date: July 31, 2001	Group Art Unit: 1645 1631
cor	266.	Wang et al., Arch. Toxicol., 71: 638	-645 (1997)	(ABSTRACT ONLY)
)	267.	Watanabe et al., Biochem. Pharmac	ol., <b>60</b> : 285-291 (2000)	
	268.	Watanabe et al., Free Radic. Biol. M	Med., 30: 1019-1028 (2001)	
	269.	Weber et al., Chemosphere, 30: 263	5-2641 (1998)	
	270.	Weber et al., Chemosphere, 30: 629	-639 (1995)	
	271.	Williams et al., Biochem. Pharmaco	ol., <b>49</b> : 209-17 (1995)	
	272.	Williams et al., Drug Chem. Toxico	l., <b>21</b> : 449-476 (1998)	
-	273.	Wong et al., Toxicol. Appl. Pharma	col., 153: 109-118 (1998)	
	274.	Woodcroft & Novak, Drug Metab.	Dispos., <b>26</b> : 372-378 (1998)	
	275.	Wormser & Calp, Toxicology., 53: 3	323-329 (1988)	
	276.	Wroblewski & Olson, Drug Metab.	Dispos., 16: 43-51 (1988)	
	277.	Xiong et al., Life Sci., 65: 421-430 (	(1999)	
	278.	Yamada et al., Life Sci., 61: 171-179	9 (1997)	
	279.	Yamamura et al., Drug Metab. Disp	pos., <b>27</b> : 724-730 (1999)	
	280.	Yasuhara et al., Toxicol. Appl. Phar	rmacol., <b>79</b> : 453-460 (1985)	
	281.	Yoshida & Suzuki, Eur. J. Pharmac	col., <b>250</b> : 117-124 (1993)	
	282.	Yoshida et al., Eur. J. Pharmacol., 2	214: 247-252 (1992)	
	283.	Zeiger et al., Mutat. Res., 393: 189-	197 (1997)	
	284.	Zhu et al., Neurosci. Lett., 95: 252-2	256 (1988)	
Examine	C	Seyun	Date Considered 4/	28/03
Examine	:: Ini thr	tial if reference considered, whether ough citation if not in conformance mmunication to applicant.	er or not citation is in confor	mance with MPEP 609; draw line

TANKOP	MATI	ON DISCLOSUE	E CITATION	Attorney Docket		Amplication	Na	
ONFORMATION DISCLOSURE CITATION				44921-5038	Application No. <b>09/917,800</b>			
MAR 0 5 2003 (Use several sheets if necessary)				Applicant: Donna MENDRICK et al.				
PTO Form 1449					Group Art Unit: 1645 1631			
A TOP	MACH OF		U.S. PATE	NT DOCUMENTS				.051
Initial		Patent No.	Issue Date	Name	Class	Sub- class	Filin	g Date
						•	#	72
	1						里 🗷	TIT-
							第 章	$\mathcal{C}$
							1 -	<del>- III-</del>
							罗。	、こ
			FOREIGN PA	TENT DOCUMENT	ΓS		CENTER 1600	夏四
		Document No.	Publication Date	Country	Class	Sub- class	Transl	ation No
al	1.	WO 01/02609.	11 Jan 01	PCT		-		
				,	_			-/4
					-			
			OTHER	DOCUMENTS	<del></del>		<b>-</b>	
cor	2.	Schilter, B. et al. Activation of cytochrome P450 gene expression in rat brain by phenobarbital-like inducers. J Pharmacol Exp Ther 294(3):916-22 (Sept. 2000). Abstract only.						
	3.							
	4.							
	5.		· · · · · · · · · · · · · · · · · · ·					
Examiner Jumbs			Date Considered 4/24/87					
Examiner:	Ini	itial if reference co	onsidered, whether	or not citation is in c	onformanc	e with MPE	P 609; dra	w line
	thı	rough citation if no	ot in conformance	and not considered. I				
communication to applicant.								